Natural vs. Lab-Grown Diamonds: Market Positioning, Value Retention, and Disclosure Risk

The distinction between natural and laboratory-grown diamonds has become one of the most consequential issues in the contemporary jewelry market. As lab-grown diamond production has scaled dramatically since 2018, wholesale prices for lab-grown stones have declined by more than 80% in some size categories, fundamentally altering the resale landscape and creating significant disclosure obligations for both sellers and advisors.

This analysis examines how natural and lab-grown diamonds compare across five critical dimensions: market positioning, value retention over time, resale liquidity, insurance documentation requirements, and disclosure obligations under current industry and legal standards.

Natural diamonds derive value from geological scarcity, formation timelines measured in billions of years, and a global supply chain constrained by finite mine output. This scarcity premium has historically underpinned resale values and collector interest.

Lab-grown diamonds are chemically and optically identical to natural diamonds, but their production can be scaled to meet demand. As manufacturing capacity has increased globally — particularly from Chinese producers — wholesale prices for lab-grown diamonds have fallen precipitously. A 1-carat lab-grown diamond that retailed for $3,000 in 2020 may now retail for under $500.

This price compression has created a significant repositioning challenge for the market. Some retailers have embraced lab-grown diamonds as an accessible alternative; others have exited the category entirely in favor of positioning natural diamonds as the premium, irreplaceable choice.

Natural diamonds, particularly those with strong color, clarity, and provenance documentation, have demonstrated resilience as stores of value, especially in the D-to-F color and VS2-and-above clarity ranges. Exceptional stones — notably fancy colored natural diamonds — have appreciated significantly at major auction houses over the past two decades.

Lab-grown diamonds, by contrast, have not demonstrated value retention. The secondary market for lab-grown diamonds remains thin, with resale prices often representing a fraction of original purchase price. As manufacturing costs continue to decline, there is no natural floor mechanism comparable to mining economics for natural stones.

For clients acquiring diamonds as part of an estate plan, insurance program, or long-term wealth preservation strategy, this distinction is material and should be disclosed clearly at the point of sale.

Insurance underwriting for diamonds requires accurate identification of whether a stone is natural or laboratory-grown. Most major insurers now require explicit disclosure on appraisal documents. A natural diamond and a lab-grown diamond of equivalent size and apparent quality will carry materially different replacement values.

GSBH appraisals include standard disclosure language identifying the origin status of every stone — natural, laboratory-grown, simulant, or undetermined pending testing. Clients should ensure that all existing appraisal documentation reflects current origin determinations, particularly for stones purchased or appraised before 2020, when laboratory identification protocols were less consistently applied.

Federal Trade Commission guidelines, updated in 2018, require that sellers disclose when a diamond is laboratory-grown. The FTC has also confirmed that laboratory-grown diamonds may be called "diamonds" without qualification, provided the qualifier "laboratory-grown," "lab-created," or equivalent language is used.

For estate sales, trust distributions, and charitable donations, the valuation type used must be appropriate to the transaction. A lab-grown diamond appraised at insurance replacement value may carry a significantly higher stated value than its fair market value — a distinction that has tax and fiduciary implications if not managed carefully.

Several recurring misunderstandings affect clients, estate professionals, and advisors:

Misunderstanding 1: "Lab-grown diamonds hold value like natural diamonds." They do not. The secondary market for lab-grown stones is thin and declining in price.

Misunderstanding 2: "GIA certification means the stone is natural." GIA certifies both natural and lab-grown diamonds. The report will specify which type it is — clients should always verify this explicitly.

Misunderstanding 3: "Older appraisals don't need to be updated." Pre-2020 appraisals may predate standardized lab-grown identification. Any collection with stones purchased in the 2015–2020 window should be reviewed.

Misunderstanding 4: "Insurance coverage is the same regardless of origin." Coverage terms and replacement values differ materially between natural and lab-grown stones.

GSBH takes no position on the personal choice between natural and lab-grown diamonds. Both have legitimate uses, and clients should make informed decisions based on their individual priorities — aesthetic, financial, ethical, or environmental.

What GSBH does insist upon is accurate, documented disclosure. Every appraisal, insurance document, and estate inventory should clearly identify the origin status of each stone. Clients who are uncertain about the status of stones in their collection should schedule a review.

For estate and fiduciary advisors, we recommend treating any collection without current, compliant appraisal documentation as a disclosure risk — particularly in the current environment where lab-grown stones have become widespread without always being clearly labeled.

1. Review existing appraisals. Any appraisal more than three years old, or predating 2020, should be reviewed for compliance with current disclosure standards.

2. Confirm origin documentation. For significant stones, ensure GIA or equivalent laboratory reports confirm natural vs. lab-grown status.

3. Update insurance schedules. Ensure replacement values reflect accurate origin status and current market conditions.

4. Consult an independent appraiser. For estate, legal, or fiduciary purposes, use an independent, certified appraiser with no conflict of interest in the transaction.

Contact GSBH to schedule a private review of your collection, estate inventory, or specific stones of concern.